

TRACER (S1415CD) NEWSLETTER



May 2018

STUDY UPDATES

- ✦ As of 05/21/2018, we have 1,770 patients registered across 44 components (all Cohort components, 7 out of 8 Usual Care components, all Intervention Arm 3 components, and all Intervention Arm 4 components).

CONGRATULATIONS AND THANK YOU TO OUR TOP ACCRUERS

These sites have reached at least 75% of their overall accrual:

- ★ St. Luke's Mountain States Tumor Institute in Boise, ID
- ★ Geisinger Medical Center in Danville, PA
- ★ Sanford Medical Center in Fargo, ND
- ★ John H. Stroger Jr. Hospital of Cook County in Chicago, IL

These sites have reached at least 90% of their overall accrual:

- ★ Illinois Cancer Care in Peoria, IL
- ★ Cancer Care Specialists of Central Illinois in Decatur, IL
- ★ Carle Cancer Center in Urbana, IL

TrACER: A Pragmatic Trial Assessing CSF Prescribing Effectiveness and Risk

This pragmatic trial is designed to test an intervention to increase compliance with guidelines, and generate evidence to assess effectiveness of Primary Prophylactic CSF (PP-CSF) on reducing rates of FN for patients receiving intermediate-risk chemotherapy regimens. TrACER is the first trial of its kind and is sponsored by SWOG, a part of the National Clinical Trials Network. The trial is led by Dr. Scott Ramsey at HICOR and funded in part by PCORI.


HIGHLIGHT ON DOCTORS' CANCER CENTER

Despite facing devastation from two major hurricanes, Doctors' Cancer Center in Manati, Puerto Rico is one of TrACER's fastest accruing sites. The TrACER study team had the pleasure of meeting with the team at Doctors' Cancer Center to discuss what has made them so successful. Best practices at Doctors' Cancer Center include:


- An internal protocol for TrACER that reviews the study background, eligibility criteria, and the Doctors' Cancer Center workflow.
- Strong communication between the oncologist and study team to identify eligible patients.
- A case worker who alerts the study team of eligible patients if the MD misses the opportunity.
- Review of protocol every two months by study principal investigator in all-staff meetings.

The staff at Doctors' Cancer Center is willing to share their internal protocol with interested sites. Please contact the TrACER study team if you are interested in receiving a copy.

TrACER Total Accrual as of May 21, 2018



TrACER Accrual in the Past 12 Months



Contact Us

Site Requirements, including regimen questions: HICOR ▪ TrACER@fredhutch.org ▪ 206-667-7624
 Patient eligibility, study procedures, and data submission:
 SWOG SDMC ▪ cancercontrolquestion@crab.org ▪ 206-652-2267